{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T05:53:54Z","timestamp":1778910834622,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"vor","delay-in-days":731,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jcf.2022.09.002","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T23:41:29Z","timestamp":1662594089000},"page":"1066-1069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Drug-induced acne with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6410-4931","authenticated-orcid":false,"given":"Brionna N.","family":"Hudson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hollyann R.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5210-423X","authenticated-orcid":false,"given":"Alexander","family":"Philbrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6177-2472","authenticated-orcid":false,"given":"Xiaolong A.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle M.","family":"Simonsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1968-4583","authenticated-orcid":false,"given":"Julie A.","family":"Safirstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannon M.","family":"Rotolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jcf.2022.09.002_bib0001","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.pcl.2016.04.001","article-title":"Background and epidemiology","volume":"63","author":"Sanders","year":"2016","journal-title":"Pediatr Clin N Am"},{"issue":"2","key":"10.1016\/j.jcf.2022.09.002_bib0002","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/j.1525-1470.2008.00620.x","article-title":"Cutaneous manifestations of cystic fibrosis","volume":"25","author":"Bernstein","year":"2008","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"10.1016\/j.jcf.2022.09.002_bib0003","doi-asserted-by":"crossref","first-page":"149","DOI":"10.5152\/cjms.2018.596","article-title":"Skin findings in cystic fibrosis cases","volume":"3","author":"Daye","year":"2018","journal-title":"Cyprus J Med Sci"},{"issue":"2","key":"10.1016\/j.jcf.2022.09.002_bib0004","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.clindermatol.2016.10.007","article-title":"Drug-induced acne","volume":"35","author":"Kazandjieva","year":"2017","journal-title":"Clin Dermatol"},{"issue":"21","key":"10.1016\/j.jcf.2022.09.002_bib0005","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa0909825","article-title":"Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation","volume":"363","author":"Accurso","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcf.2022.09.002_bib0006","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet N Am Ed"},{"key":"10.1016\/j.jcf.2022.09.002_bib0007","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor\u2013Tezacaftor\u2013Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jcf.2022.09.002_bib0008","doi-asserted-by":"crossref","first-page":"e04116","DOI":"10.1002\/ccr3.4116","article-title":"Novel reaction to new cystic fibrosis medication Trikafta","volume":"9","author":"Stashower","year":"2021","journal-title":"Clin Case Rep"},{"issue":"1156","key":"10.1016\/j.jcf.2022.09.002_bib0009","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1136\/postgradmedj-2020-139264","article-title":"\u2018Triple therapy\u2019 (elexacaftor, tezacaftor, ivacaftor) skin rash in patients with cystic fibrosis","volume":"98","author":"Hu","year":"2022","journal-title":"Postgrad Med J"},{"issue":"8","key":"10.1016\/j.jcf.2022.09.002_bib0010","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1002\/ppul.25437","article-title":"CFTR modulator drug desensitization: preserving the hope of long term improvement","volume":"56","author":"Leonhardt","year":"2021","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.jcf.2022.09.002_bib0011","first-page":"463","article-title":"Rechallenge of elexacaftor\/tezacaftor\/ivacaftor after skin rash in two pediatric patients","volume":"27","author":"Diseroad","year":"2022","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"22","key":"10.1016\/j.jcf.2022.09.002_bib0012","article-title":"A case of Elexacaftor-Tezacaftor-Ivacaftor induced rash resolving without interruption of treatment","volume":"S1569-1993","author":"Bhaskaran","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.09.002_bib0013","unstructured":"Witworth, J. \u201cDealing with Trikafta acne\u201d. Cystic-Fibrosis.Com. 4 March 2021, cystic-fibrosis.com\/living\/trikafta-acne. Accessed 2 August 2022."},{"key":"10.1016\/j.jcf.2022.09.002_bib0014","unstructured":"r\/CysticFibrosis \u201cAcne \/trikafta\u201d redditt. reddit.com\/r\/CysticFibrosis\/comments\/elz95o\/acne_trikafta\/. Accessed 2 August 2022."},{"key":"10.1016\/j.jcf.2022.09.002_bib0015","unstructured":"Livingston, Jenny. \u201cReal talk tuesday: trikafta acne\u201d. Instagram. 23 June 2020, .instagram.com\/p\/CBylHiQjoUj\/?hl=en. Accessed 2 August 2022."},{"issue":"3","key":"10.1016\/j.jcf.2022.09.002_bib0016","doi-asserted-by":"crossref","DOI":"10.5070\/D3223030371","article-title":"Isotretinoin therapy for the treatment of acne in patients with cystic fibrosis: a case series and review of the literature","volume":"22","author":"Bari","year":"2016","journal-title":"Dermatol Online J"},{"issue":"8","key":"10.1016\/j.jcf.2022.09.002_bib0017","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1136\/adc.2008.156406","article-title":"Treatment of acne with oral isotretinoin in patients with cystic fibrosis","volume":"94","author":"Perera","year":"2009","journal-title":"Arch Dis Child"},{"issue":"4","key":"10.1016\/j.jcf.2022.09.002_bib0018","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaad.2006.08.048","article-title":"American Academy of Dermatology\/American Academy of Dermatology Association. Guidelines of care for acne vulgaris management","volume":"56","author":"Strauss","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"21","key":"10.1016\/j.jcf.2022.09.002_bib0019","first-page":"02131","article-title":"A restructuring of microbiome niche space is associated with Elexacaftor\u2013Tezacaftor\u2013Ivacaftor therapy in the cystic fibrosis lung","volume":"S1569-1993","author":"Sosinski","year":"2021","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2022.09.002_sbref0020","series-title":"Skin microbiome of children with cystic fibrosis","author":"Pybus","year":"2016"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322006579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199322006579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:47:02Z","timestamp":1761601622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199322006579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":20,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S1569199322006579"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2022.09.002","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Drug-induced acne with elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2022.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Cystic Fibrosis Society. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}